Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Seroconversion rates following COVID-19 vaccination among patients with cancer
Astha Thakkar, Jesus D. Gonzalez‐Lugo, Niyati Goradia, et al.
Cancer Cell (2021) Vol. 39, Iss. 8, pp. 1081-1090.e2
Open Access | Times Cited: 341

Showing 1-25 of 341 citing articles:

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
Alfredo Addeo, Pankil Shah, Natacha Bordry, et al.
Cancer Cell (2021) Vol. 39, Iss. 8, pp. 1091-1098.e2
Open Access | Times Cited: 227
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
Matthias B. Moor, Franziska Suter‐Riniker, Michael P. Horn, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 11, pp. e789-e797
Open Access | Times Cited: 200
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
Oliver Van Oekelen, Charles Gleason, Sarita Agte, et al.
Cancer Cell (2021) Vol. 39, Iss. 8, pp. 1028-1030
Open Access | Times Cited: 199
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche, Liêm Binh Luong Nguyen, Éric Tartour, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 163-177
Open Access | Times Cited: 175
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
Nature Cancer (2021) Vol. 2, Iss. 12, pp. 1305-1320
Open Access | Times Cited: 158
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
Yair Herishanu, Galia Rahav, Shai Levi, et al.
Blood (2021) Vol. 139, Iss. 5, pp. 678-685
Open Access | Times Cited: 110
COVID-19 in patients with hematologic malignancy
Petra Langerbeins, Michael Hallek
Blood (2022) Vol. 140, Iss. 3, pp. 236-252
Open Access | Times Cited: 108
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis
Andrea Becerril‐Gaitan, Bryan F. Vaca‐Cartagena, Ana S. Ferrigno, et al.
European Journal of Cancer (2021) Vol. 160, pp. 243-260
Open Access | Times Cited: 106
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer
Lauren C. Shapiro, Astha Thakkar, Sean Campbell, et al.
Cancer Cell (2021) Vol. 40, Iss. 1, pp. 3-5
Open Access | Times Cited: 103
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)
Ghady Haidar, Mounzer Agha, Andrew Bilderback, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 1, pp. e630-e644
Open Access | Times Cited: 81
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Sean H. Lim, Beth Stuart, Débora Joseph‐Pietras, et al.
Nature Cancer (2022) Vol. 3, Iss. 5, pp. 552-564
Open Access | Times Cited: 68
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants
Fábio Mambelli, Ana Carolina V. S. C. de Araujo, Jéssica Pires Farias, et al.
Pathogens (2025) Vol. 14, Iss. 1, pp. 23-23
Open Access | Times Cited: 1
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
Sjoukje F. Oosting, Astrid A.M. van der Veldt, Corine H. GeurtsvanKessel, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 12, pp. 1681-1691
Open Access | Times Cited: 97
COVID-19 vaccination and breakthrough infections in patients with cancer
Andrew Schmidt, Chris Labaki, Chih–Yuan Hsu, et al.
Annals of Oncology (2021) Vol. 33, Iss. 3, pp. 340-346
Open Access | Times Cited: 94
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
Annika Fendler, Lewis Au, Scott T.C. Shepherd, et al.
Nature Cancer (2021) Vol. 2, Iss. 12, pp. 1321-1337
Open Access | Times Cited: 82
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
Chiara Corti, Gabriele Antonarelli, Florian Scotté, et al.
Annals of Oncology (2021) Vol. 33, Iss. 2, pp. 158-168
Open Access | Times Cited: 70
Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer
Julie Wu, Jennifer La, Westyn Branch‐Elliman, et al.
JAMA Oncology (2021) Vol. 8, Iss. 2, pp. 281-281
Open Access | Times Cited: 70
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
Joanne S. K. Teh, Julien Coussement, Zoe C. F. Neoh, et al.
Blood Advances (2021) Vol. 6, Iss. 7, pp. 2014-2034
Open Access | Times Cited: 70
A ‘mix and match’ approach to SARS-CoV-2 vaccination
Meagan E. Deming, Kirsten E. Lyke
Nature Medicine (2021) Vol. 27, Iss. 9, pp. 1510-1511
Closed Access | Times Cited: 66
Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients
Simeon Schietzel, Manuel Anderegg, Andreas Limacher, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002036-e002036
Open Access | Times Cited: 66
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis
Son Tran, Tony H. Truong, Aru Narendran
European Journal of Cancer (2021) Vol. 159, pp. 259-274
Open Access | Times Cited: 65
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
Nico Gagelmann, Francesco Passamonti, Christine Wolschke, et al.
Haematologica (2021) Vol. 107, Iss. 8, pp. 1840-1849
Open Access | Times Cited: 65
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis
Thomas Hueso, Anne-Sophie Godron, Émilie Lanoy, et al.
Leukemia (2022) Vol. 36, Iss. 4, pp. 1025-1034
Open Access | Times Cited: 61
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study
Vivek Naranbhai, Claire A. Pernat, Alexander Gavralidis, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 1, pp. 12-23
Open Access | Times Cited: 61
Page 1 - Next Page

Scroll to top